Duopharma Biotech To Manufacture Its Second Oncology Medicine To Treat Chronic Myeloid Leukemia
Shah Alam, September 15, 2020 – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary, Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam, to help address the paucity of affordable alternatives to treat cancer.